ZA200308630B - Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases. - Google Patents
Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases. Download PDFInfo
- Publication number
- ZA200308630B ZA200308630B ZA200308630A ZA200308630A ZA200308630B ZA 200308630 B ZA200308630 B ZA 200308630B ZA 200308630 A ZA200308630 A ZA 200308630A ZA 200308630 A ZA200308630 A ZA 200308630A ZA 200308630 B ZA200308630 B ZA 200308630B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- dimethylamine
- pirazole
- ethoxy
- thienylmethyl
- Prior art date
Links
- 208000023504 respiratory system disease Diseases 0.000 title claims description 10
- 125000003118 aryl group Chemical group 0.000 title claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 60
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 19
- 206010011224 Cough Diseases 0.000 claims description 15
- -1 thienyl radical Chemical class 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 7
- 201000009961 allergic asthma Diseases 0.000 claims description 7
- 201000010105 allergic rhinitis Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 7
- 206010006451 bronchitis Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 claims description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000000954 anitussive effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 7
- 230000001624 sedative effect Effects 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 229940124584 antitussives Drugs 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003434 antitussive agent Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200100817A ES2174756B2 (es) | 2001-04-06 | 2001-04-06 | Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200308630B true ZA200308630B (en) | 2004-11-05 |
Family
ID=8497368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200308630A ZA200308630B (en) | 2001-04-06 | 2003-11-05 | Azolylcarbynol derivatives of aryl (or heteroaryl) for the treatment of respiratory diseases. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20040142994A1 (fr) |
| EP (1) | EP1384476B1 (fr) |
| JP (1) | JP2004531511A (fr) |
| KR (1) | KR20040025913A (fr) |
| CN (1) | CN1230165C (fr) |
| AT (1) | ATE289812T1 (fr) |
| AU (1) | AU2002246151B2 (fr) |
| BR (1) | BR0208807A (fr) |
| CA (1) | CA2443015A1 (fr) |
| DE (1) | DE60203106T2 (fr) |
| DK (1) | DK1384476T3 (fr) |
| ES (2) | ES2174756B2 (fr) |
| HU (1) | HUP0400925A3 (fr) |
| IL (1) | IL158268A0 (fr) |
| MX (1) | MXPA03009125A (fr) |
| NO (1) | NO20034471L (fr) |
| NZ (1) | NZ529303A (fr) |
| PL (1) | PL365251A1 (fr) |
| PT (1) | PT1384476E (fr) |
| RU (1) | RU2294198C2 (fr) |
| WO (1) | WO2002080908A1 (fr) |
| ZA (1) | ZA200308630B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10335566A1 (de) * | 2003-07-31 | 2005-02-24 | Grünenthal GmbH | Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen |
| EP1584335A3 (fr) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Combinaison de substances actives comprenant un composé carbinol et un opioïde |
| ES2244326B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
| EP1784178A1 (fr) * | 2004-07-30 | 2007-05-16 | Laboratorios Del Dr. Esteve, S.A. | Aryl (ou heteroaryl) azolylcarbinols |
| EP1632227A1 (fr) * | 2004-09-07 | 2006-03-08 | Laboratorios del Dr. Esteve S.A. | Dérivés des aryl (ou des heteroaryl) azolylcarbinols (en particulier cizolirtin citrate) pour le traitement de la dépendance des opioides |
| EP1820502A1 (fr) * | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Combinaisons de principes actifs comprenant de dérivés d' azolylcarbinol |
| WO2010123999A2 (fr) * | 2009-04-21 | 2010-10-28 | Auspex Pharmaceuticals, Inc. | Modulateurs 1-méthylpyrazole de la substance p, du peptide apparenté au gène de la calcitonine, des récepteurs adrénergiques et/ou des récepteurs 5-ht |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2150353B1 (es) * | 1998-04-15 | 2001-07-01 | Esteve Labor Dr | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos. |
| ES2137136B1 (es) * | 1998-05-18 | 2000-07-01 | Esteve Labor Dr | Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica. |
| ES2150378B1 (es) * | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
-
2001
- 2001-04-06 ES ES200100817A patent/ES2174756B2/es not_active Expired - Fee Related
-
2002
- 2002-03-21 CN CNB028098943A patent/CN1230165C/zh not_active Expired - Fee Related
- 2002-03-21 IL IL15826802A patent/IL158268A0/xx unknown
- 2002-03-21 AT AT02714232T patent/ATE289812T1/de not_active IP Right Cessation
- 2002-03-21 ES ES02714232T patent/ES2236497T3/es not_active Expired - Lifetime
- 2002-03-21 AU AU2002246151A patent/AU2002246151B2/en not_active Ceased
- 2002-03-21 DE DE60203106T patent/DE60203106T2/de not_active Expired - Fee Related
- 2002-03-21 BR BR0208807-0A patent/BR0208807A/pt not_active IP Right Cessation
- 2002-03-21 CA CA002443015A patent/CA2443015A1/fr not_active Abandoned
- 2002-03-21 RU RU2003132456/15A patent/RU2294198C2/ru not_active IP Right Cessation
- 2002-03-21 PT PT02714232T patent/PT1384476E/pt unknown
- 2002-03-21 PL PL02365251A patent/PL365251A1/xx not_active Application Discontinuation
- 2002-03-21 JP JP2002578947A patent/JP2004531511A/ja not_active Withdrawn
- 2002-03-21 HU HU0400925A patent/HUP0400925A3/hu unknown
- 2002-03-21 WO PCT/ES2002/000136 patent/WO2002080908A1/fr active IP Right Grant
- 2002-03-21 MX MXPA03009125A patent/MXPA03009125A/es active IP Right Grant
- 2002-03-21 DK DK02714232T patent/DK1384476T3/da active
- 2002-03-21 EP EP02714232A patent/EP1384476B1/fr not_active Expired - Lifetime
- 2002-03-21 NZ NZ529303A patent/NZ529303A/en unknown
- 2002-03-21 KR KR10-2003-7013063A patent/KR20040025913A/ko not_active Application Discontinuation
- 2002-03-21 US US10/474,232 patent/US20040142994A1/en not_active Abandoned
-
2003
- 2003-10-06 NO NO20034471A patent/NO20034471L/no not_active Application Discontinuation
- 2003-11-05 ZA ZA200308630A patent/ZA200308630B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60203106D1 (de) | 2005-04-07 |
| PT1384476E (pt) | 2005-05-31 |
| CN1535147A (zh) | 2004-10-06 |
| NZ529303A (en) | 2005-06-24 |
| DK1384476T3 (da) | 2005-05-30 |
| NO20034471D0 (no) | 2003-10-06 |
| DE60203106T2 (de) | 2006-04-13 |
| EP1384476B1 (fr) | 2005-03-02 |
| ES2236497T3 (es) | 2005-07-16 |
| JP2004531511A (ja) | 2004-10-14 |
| AU2002246151B2 (en) | 2007-05-31 |
| EP1384476A1 (fr) | 2004-01-28 |
| CN1230165C (zh) | 2005-12-07 |
| NO20034471L (no) | 2003-12-03 |
| US20040142994A1 (en) | 2004-07-22 |
| KR20040025913A (ko) | 2004-03-26 |
| IL158268A0 (en) | 2004-05-12 |
| WO2002080908A1 (fr) | 2002-10-17 |
| HUP0400925A2 (hu) | 2004-07-28 |
| RU2294198C2 (ru) | 2007-02-27 |
| ATE289812T1 (de) | 2005-03-15 |
| ES2174756B2 (es) | 2003-11-16 |
| MXPA03009125A (es) | 2005-04-11 |
| HUP0400925A3 (en) | 2004-10-28 |
| ES2174756A1 (es) | 2002-11-01 |
| CA2443015A1 (fr) | 2002-10-17 |
| BR0208807A (pt) | 2004-07-13 |
| AU2002246151C1 (en) | 2002-10-21 |
| PL365251A1 (en) | 2004-12-27 |
| RU2003132456A (ru) | 2005-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA004657B1 (ru) | Фармацевтическая композиция на основе обладающих антихолинергическим действием соединений , способ ее получения и применение | |
| EP0481675A2 (fr) | Préparation de médicaments pour le traitement de l'asthme, utilisant la (S)-alpha-fluorométhylhistidine et ses esters | |
| WO2012054813A1 (fr) | Nouvelles méthodes de traitement des troubles ou des maladies respiratoires | |
| SK7899A3 (en) | Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an hmg-coa-reductase inhibitor | |
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| SK127399A3 (en) | Antitussive compositions | |
| US12064410B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory | |
| KR20190099245A (ko) | Task-1 및 task-3 채널 억제제를 함유하는 제약 투여 형태, 및 호흡 장애 요법에서의 그의 용도 | |
| EP1384476B1 (fr) | Derives d'aryle (ou heteroaryle) azolylcarbinoles pour le traitement de maladies respiratoires | |
| RU2493851C2 (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинестеразы, содержащая ее фармацевтическая композиция и ее применение в лечении когнитивных расстройств | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| KR100197065B1 (ko) | 백내장의 예방 및 치료약 | |
| US10543187B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| KR100192534B1 (ko) | 소마토스타틴 분비증가제와 분비저하 억제제 | |
| CN1291891A (zh) | 治疗肺慢性阻塞性疾病的方法 | |
| US20080096870A1 (en) | Methods and Materials for Treating Mental Illness | |
| US12083089B2 (en) | Compositions and methods for stimulating ventilatory and/or respiratory drive | |
| WO2005123694A2 (fr) | Composes organiques | |
| WO2024102447A1 (fr) | Utilisations de dérivés d'hydroimidazopyridopyrimidinone pour la gestion d'anévrismes ou d'autres états ou maladies vasculaires | |
| EP1611888A1 (fr) | Antitussifs | |
| EP1218008A2 (fr) | Nouvelle utilisation de 1,2,4-triazolo[1,5-a]pyrimidines | |
| JPWO2005011674A1 (ja) | 気管支喘息の予防及び／または治療剤 | |
| JPH06192090A (ja) | 抗喘息薬 | |
| US20110201659A1 (en) | Agent for preventing or treating zoster-associated pain | |
| JP2001199891A5 (fr) |